text.skipToContent text.skipToNavigation

LGC acquires Immunosuppressive PT scheme

Date:11 October 2016

I am delighted to announce that LGC has acquired the world-leading immunosuppressive proficiency testing (PT) scheme from ASI. Currently operated from St George’s, University of London, the scheme will be fully integrated into our existing clinical PT offering operating from Bury.

This acquisition strengthens our position in the clinical market, complementing last year’s acquisition of Thistle QA (PT) in South Africa, and Maine Standards (calibration verification materials) in the US.

ASI’s PT scheme is not new to us. We have been producing and shipping the samples used in the scheme, as well as being a global distributor in a number of key geographies (except the UK, France and Italy) for the last six years. With more than 800 participants in 60 countries, ASI is the global leader in the provision of PT for immunosuppressive drugs and has been a pioneer in this field over the last 30 years. This is a niche market in the clinical sector, which is not covered by many of our competitors. The acquisition does not involve any employee transfers; however, Prof David Holt, one of the three founders of the scheme, is to remain closely associated with its onward running and development.

Brian Brookman and his team will ensure a smooth transition in the next few months and we expect the scheme will be fully integrated in our portfolio by January 2017.



Refine your


Online Ordering made easy


Sign up to our email newsletter



Punchout session timeout warning

Your punchout session will expire in 1 min 59 sec.

Select "Continue session" to extend your session.